Physician profile
Deborah Monzyk
NPI 1457350381
$1,571.31
in general payments reported to CMS, 2019-2025
11 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $400 · 2023: $231 · 2024: $204 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902 · Education: $91.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.90 |
| Education | $91.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $387.11 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $365.58 | 2021-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $227.22 | 2024-2025 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.95 | 2021-2025 | Caplyta |
| Abbvie INC. | $108.18 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $102.45 | 2021-2022 | |
| Alkermes, INC. | $80.38 | 2022 | |
| Indivior INC. | $60.68 | 2021-2023 | Perseris |
| Vanda Pharmaceuticals INC. | $42.24 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $16.62 | 2022 | |
| Neurocrine Biosciences, INC. | $13.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Monzyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.